Released Aug 11, 2025, after the close
10-Q filed Aug 11, 2025, 42 days after period end · 0001708599-25-000089
Q2 2025 · 10-Q
Revenue$130.00K$130.00K +154.9% vs Q2 2024no prior Q1 2025 on file
Net Income-$6.45M-$6.45M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.66-$0.66 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$5,565,000N/M
Operating Cash Flowderived-$3,750,000N/M
Free Cash Flowderived-$3,796,000N/M
Margins · derived
Operating margin-4280.8%+3299.6 pt vs Q2 2024
Net margin-4960.0%
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $130.00K | $51.00K | $7.00K | $12.00K |
| Net Income | -$6.45M | $5.20M | $808.00K | -$2.62M |
| EPS Diluted | -$0.66 | $0.51 | $0.11 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Serina Therapeutics, Inc. · CIK 1708599 · Engraved from SEC EDGAR